Infrastructure Provider – basic structures and facilities needed for the operation of society, e.g. roads and airports, education, and legal systems. Intellectual property, which is something unique that is created, is foundational for some emerging industries.

Policy Gap – preventing government support from extending from the provision of infrastructure in general to funding and procurement for a particular emerging industry. Clear and consistent policy can bridge the policy gap.

Gregory Theyel, Ph.D. Professor

[email protected]

Funder and Customer – patient grant funding and procurement contracts.

Process Gap – the delay between research and development and commercialization, possibly in the form of slow approval of a drug or a device or in the form of political opposition of an industry.

Gregory Theyel, Ph.D. Professor

[email protected]

Regulator – safety, resource protection, & fairness are primary regulatory objectives.

Gregory Theyel, Ph.D. Professor

[email protected]

Gregory Theyel, Ph.D. Professor

[email protected]

Gregory Theyel, Ph.D. Professor

[email protected]

Genomics Industry

Case: Conn, J. and Siegel, R. (2020) "23andMe: A Virtuous Loop" Stanford University Business School, E688-PDF-ENG.

Assignment 6: Describe the government mechanisms that have affected the genomics industry, and propose a strategic direction for 23andMe that leverages these government influences. (In order to receive credit, limit your answer to 500 or fewer words and submit it via Blackboard prior to class, Thursday, November 18, 2021. No late assignments will be accepted.)

Gregory Theyel, Ph.D. Professor

[email protected]

Final Report

1) How do firm strategy, technology, investment, supply networks, production, markets, and government affect the emergence of your chosen industry? Use Figure 1.1 Framework for Understanding Industry Emergence (Theyel, 2017) to illustrate the state of each element for your chosen industry.

2) Describe firm, investor, and government opportunities based on analysis of your chosen emerging industry.

Gregory Theyel, Ph.D. Professor

[email protected]

Industry Report

1a) Firm Strategy - How does firm strategy affect the emergence of your chosen industry?

1b) Technology - How does technology affect the emergence of your chosen industry?

1c) Investment - How does investment affect the emergence of your chosen industry?

1d) Supply Networks - How do supply networks affect the emergence of your chosen industry?

1e) Production - How does production affect the emergence of your chosen industry?

1f) Markets - How do markets affect the emergence of your chosen industry?

1g) Government - How does government affect the emergence of your chosen industry?

2a) Firms- Describe firm opportunities based on analysis of your chosen emerging industry.

2b) Investors - Describe investor opportunities based on analysis of your chosen emerging industry.

2c) Government - Describe government opportunities based on analysis of your chosen emerging industry.

Citations

Appendices

Gregory Theyel, Ph.D. Professor

[email protected]

Gregory Theyel, Ph.D. Professor

[email protected]

Appendix A

Gregory Theyel, Ph.D. Professor

[email protected]

Firm Strategy – Regenerative Medicine Industry

Commodity

Specialty

Low High

Revenue

>$50M

$5-$50M

$0-$5M

Appendix B

Gregory Theyel, Ph.D. Professor

[email protected]

Regenerative Medicine

Appendix C

Gregory Theyel, Ph.D. Professor

[email protected]

Source: Tengien, 2013

Technology – Regenerative Medicine Industry

Appendix D

Gregory Theyel, Ph.D. Professor

[email protected]

Regenerative Medicine

Appendix E

Gregory Theyel, Ph.D. Professor

[email protected]

Appendix F

Gregory Theyel, Ph.D. Professor

[email protected]

Regenerative Medicine

Appendix G

Gregory Theyel, Ph.D. Professor

[email protected]

Investment – Regenerative Medicine Industry

Appendix H

Gregory Theyel, Ph.D. Professor

[email protected]

Regenerative Medicine

Appendix I

Gregory Theyel, Ph.D. Professor

[email protected]

Supply Networks – Regenerative Medicine Industry

Regenerative

Medicine

Firms

Govt- SBIR

Govt - FDA

Bio-Printers

Investors

Stem Cells

Laboratories

Lab Supplies

Medical

Professionals

Appendix J

Gregory Theyel, Ph.D. Professor

[email protected]

Regenerative Medicine

Appendix K

Gregory Theyel, Ph.D. Professor

[email protected]

Regenerative Medicine

Appendix L

Gregory Theyel, Ph.D. Professor

[email protected]

Markets – Regenerative Medicine Industry

Commodity

Specialty

Low High

Cost

Skin

Cartilage

Organs

Visionaries

Early Adopters

Appendix M

Gregory Theyel, Ph.D. Professor

[email protected]

Regenerative Medicine

Appendix N

Gregory Theyel, Ph.D. Professor

[email protected]

Regenerative Medicine

Appendix O

Gregory Theyel, Ph.D. Professor

[email protected]

Tissue Engineering Industry

Gregory Theyel, Ph.D. Professor

[email protected]

Appendix P

Firms – More challenging to start a company based on new technologies after a technology standard is set; technology shortcomings can mean opportunities

Guidelines for Emerging Industry Opportunities

Gregory Theyel, Ph.D. Professor

[email protected]

Investors – Potentially few opportunities after technology standard is set and patenting declines; capital-novelty-risk assessment; segments in an industry can mean different risk

Guidelines for Emerging Industry Opportunities

Gregory Theyel, Ph.D. Professor

[email protected]

Government – Optimal to reduce government investment once private investment gains momentum; identify new early stage emerging industries to support

Guidelines for Emerging Industry Opportunities

Gregory Theyel, Ph.D. Professor

[email protected]